Immunai Collaborates with Teva to Enhance Clinical Decision Making in Clinical Trials in Immunology & Immuno-oncology

• Multi-year collaboration in immunology and immuno-oncology
  

• The partnership will utilize Immunai’s proprietary immune cell atlas, AMICA™, and the Immunodynamics Engine (IDE)™ to support decision-making in clinical trials.
  

• Key focus areas include a better understanding of drug mechanisms in action, dose selection, and biomarker analysis in clinical trials.

Immunai Inc., a leading artificial intelligence (AI) biotech company specializing in mapping the human immune system, has announced a multi-year collaboration with Teva Pharmaceuticals, an affiliate of Teva Pharmaceutical Industries Ltd. (Teva). Under this agreement, Immunai will collaborate with Teva in immunology and immuno-oncology programs.

This collaboration will leverage Immunai’s proprietary immune cell atlas, AMICA™, and its AI model, the Immunodynamics Engine (IDE)™, to enhance clinical decision-making in Teva’s Immunology trials. Key focus areas will include drug mechanism of action, dose selection, and biomarker analyses.

“This collaboration reflects our ongoing efforts in enhancing drug development within immunology and immuno-oncology. Bringing a drug to market is inherently challenging, time-consuming, and costly,” said Noam Solomon, Ph.D., CEO of Immunai. “Through our partnership with Teva, we are eager to utilize our AI-based engine, the Immunodynamics Engine (IDE)™, to streamline this process and facilitate the delivery of new therapies to patients.”

“At Teva, we are always looking to unlock what’s next in science, and working with Immunai to harness the power of their cutting-edge tools and AI solutions will help us to step up innovation to drive forward our research and development strategy,” said Eran Harary, MD, Senior Vice President of Global Early Clinical Development at Teva. “This collaboration will provide important insights into patient responses and treatment mechanisms in immunology and immuno-oncology, allowing us to optimize our clinical trials and improve outcomes for patients.”

The partnership also includes the potential for expanding the collaboration to encompass broader aspects of Teva’s research and development portfolio.

For more information about Immunai and partnership opportunities, please visit immunai.com.

About Immunai:
Immunai uses single-cell genomics and machine learning to discover and improve the development of novel therapeutics by decoding the immune system. With a team of over 170 experts, including 85 PhDs or MDs, the company collaborates with leading pharmaceutical firms and academic institutions. Immunai is headquartered in New York City and has raised close to $270 million in funding to date.

Contact Information

Jennifer Henry

PR for Immunai

VSC for Immunai

Contact via E-mail